Can Outpatient Worsening Heart Failure Serve as an Endpoint in Clinical Trials of Transthyretin Amyloidosis?

IF 21.7 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of the American College of Cardiology Pub Date : 2025-01-22 DOI:10.1016/j.jacc.2024.10.126

Richard K. Cheng, Douglas Leedy, Frederick L. Ruberg

引用次数: 0

Abstract

Section snippets

Funding Support and Author Disclosures

Dr Ruberg is supported by NIH grant R01HL139671; has received institutional research grant support from Akcea/Ionis Therapeutics, Anumana, Alnylam Pharmaceuticals, and Pfizer; and has received consulting fees from AstraZeneca and Attralus. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

查看原文本刊更多论文

门诊加重的心力衰竭可以作为甲状腺素淀粉样变性临床试验的终点吗？

资金支持和作者披露dr Ruberg由NIH资助R01HL139671；获得了Akcea/Ionis Therapeutics、Anumana、Alnylam Pharmaceuticals和Pfizer的机构研究资助；并获得了阿斯利康和Attralus的咨询费。所有其他作者均已报告他们与本文内容无关的关系无需披露。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American College of Cardiology 医学-心血管系统

CiteScore

42.70

自引率

3.30%

发文量

5097

审稿时长

2-4 weeks

期刊介绍： The Journal of the American College of Cardiology (JACC) publishes peer-reviewed articles highlighting all aspects of cardiovascular disease, including original clinical studies, experimental investigations with clear clinical relevance, state-of-the-art papers and viewpoints. Content Profile: -Original Investigations -JACC State-of-the-Art Reviews -JACC Review Topics of the Week -Guidelines & Clinical Documents -JACC Guideline Comparisons -JACC Scientific Expert Panels -Cardiovascular Medicine & Society -Editorial Comments (accompanying every Original Investigation) -Research Letters -Fellows-in-Training/Early Career Professional Pages -Editor’s Pages from the Editor-in-Chief or other invited thought leaders